8530498

5 known cases. View patent page →

Cases
5
Active
1
4 closed
Filed
2016–2017
Top venue
D. New Jersey
5 cases

Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc. et al.

settled
Docket:
2:17-cv-02528
Filed:
2017-04-12
Terminated:
2021-03-24

Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.

Celgene Corporation v. Dr. Reddy's Laboratories, Ltd. et al.

settled
Docket:
2:16-cv-07704
Filed:
2016-10-20
Terminated:
2020-09-17

Patent infringement action involving ANDA No. 209348; complaint expressly alleged infringement of the '800, '217, '569, '498, '095, '621 and '622 patents. Settled September 17, 2020 with volume-limited license from September 1, 2022 and unlimited from January 31, 2026.

Blue Cross Blue Shield Association plaintiffs v. Celgene Corporation et al.

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.